Patrick Lyden, MD

Professor of Physiology and Neuroscience, Neurology and Neurological Surgery

NINDS/Neuro Next Program Support

Image of Patrick Lyden, MD
Is this your profile? Click to edit

Overview

Dr. Lyden is the Professor of Physiology & Neuroscience and Neurology at the Zilkha Neurogenetic Institute in the Keck School of Medicine at USC. Dr. Lyden helped lead the pivotal NINDS t-PA for Acute Stroke Trial, the first proven therapy for stroke. He is recognized globally for leadership in stroke therapy, having led large, multi-national trials for NIH and industry. Dr. Lyden is the Principal investigator of the NINDS-sponsored Stroke Preclinical Assessment Network, or SPAN, the first multi-site trial intended to identify candidate treatments likely to succeed in human clinical trials. He is the Chair of the Stroke Council of the American Heart Association/American Stroke Association. Dr. Lyden has been elected a Fellow of the American Academy of Neurology, American Neurology Association, American Heart Association, and the European Stroke Organization. In 2019 he was awarded the prestigious William M. Feinberg Award for Excellence in Clinical Stroke by the American Heart Association. Beginning in 2023 he will lead a 100-center, $20M clinical trial of a new drug for stroke treatment in the NIH funded StrokeNet network.

Awards

  • Cedars-Sinai Medical Center: Faculty Teaching Award, 2020
  • UT Houston: Gladys & George T. Abell Lecturship in Neurology, 2019
  • American Heart Association/American Stroke Association: AHA/ASA William M. Feinberg Award for Excellence in Clinical Stroke, 2019
  • University of Iowa: Adolf L. Sahs, MD Memorial Visiting Lecturer, 2011
  • 2001
     -: Best Doctors in America, 2001
     –
  • UCSD: Department of Neurosciences Award for Outstanding Teaching, 2014
  • American Heart Association, San Diego Affiliate: Heart of Gold Award, 2002

Education and Training

  • UCLA, Los Angeles — BS — 07/1974 — Biochemistry
  • Baylor College of Medicine, Houston — MD — 061981 — Medicine
  • Mercy Hospital, San Diego — 06/1982 — Internship
  • UCSD, San Diego — 06/1985 — Neurology
  • UCSD, San Diego — 06/1987 — Vascular Neurology

Research Funding

  • Mechanisms and Treatment Implications of Differential Vulnerability in the Central Nervous System
    NIH · RF1NS146594 · Aug 18, 2026 – Jul 31, 2029 · Role: Principal Investigator
  • The NIH SPAN Coordinating Center
    NIH · U24NS130600 · Jan 1, 2023 – Dec 31, 2025 · Role: Principal Investigator
  • The NIH SPAN Coordinating Center
    NIH · U24NS113452 · Aug 1, 2019 – Jul 31, 2022 · Role: Principal Investigator
  • ZZ-3K3A-201: Safety evaluation of 3K3A-APC in ischemic stroke
    NIH · U01NS088312 · Jul 1, 2014 – Jun 30, 2019 · Role: Principal Investigator
  • Thrombin mediated cytotoxicity during cerebral ischemia
    NIH · R01NS075930 · Aug 15, 2011 – May 31, 2021 · Role: Principal Investigator
  • Quantitation of Early Vascular Leakage after Stroke
    NIH · R21NS052565 · Jul 15, 2005 – Apr 30, 2008 · Role: Principal Investigator
  • Role of Angiogenesis Following Stroke
    NIH · R01NS043300 · Dec 15, 2002 – Jun 30, 2008 · Role: Principal Investigator
  • Therapeutic Window for Acute Stroke Therapy (P50)
    NIH · P50NS044148 · Jul 1, 2002 – Apr 30, 2015 · Role: Co-Principal Investigator
  • MULTIFOCAL CEREBRAL ISCHEMIA
    NIH · R29NS026783 · Aug 1, 1989 – Jul 31, 1994 · Role: Principal Investigator

Publications

  • Pregabalin-Induced Myoclonus in a Patient Without Kidney Dysfunction. Case Rep Neurol Med. 2026; 2026:8902603.. View in PubMed
  • Vascular Neurology Fellowship: Where Do We Go From Here? Stroke. 2026 May 13. Jagolino-Cole AL, Muddasani V, Broderick JP, Coull BM, Sharrief AZ, Lyden PD , Fisher MJ , Albers GW, Grotta JC, Liebeskin . View in PubMed
  • Author Correction: Methods for randomized, blinded, controlled evaluation of putative disease interventions in multilaboratory, preclinical assessment networks. Lab Anim (NY). 2026 Apr; 55(4):151.. View in PubMed
  • Methods for randomized, blinded, controlled evaluation of putative disease interventions in multilaboratory, preclinical assessment networks. Lab Anim (NY). 2026 Mar; 55(3):74-82.. View in PubMed
  • Exploring Sex Differences in Stroke Outcomes: A Comprehensive Analysis From the SPAN 1 Trial. J Am Heart Assoc. 2026 Feb 17; 15(4):e043220.. View in PubMed
  • Feasibility of a Multi-Laboratory Model of Middle Cerebral Artery Thromboembolic Stroke with Thrombolysis: TE-MCAo. Transl Stroke Res. 2026 Jan 30; 17(1):20.. View in PubMed
  • The Stroke Preclinical Assessment Network Multi-laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo. J Vis Exp. 2025 12 19.. View in PubMed
  • Evaluating tocilizumab in ischemic stroke: Findings from the SPAN multicenter trial. Neuropharmacology. 2026 Mar 01; 285:110801.. View in PubMed
  • “Time Is Brain” – for Cell Therapies. Adv Sci (Weinh). 2026 Jan; 13(6):e19579.. View in PubMed
  • Assessing human scalp and brain blood flow sensitivities via superficial temporal artery occlusion using speckle contrast optical spectroscopy. APL Bioeng. 2025 Dec; 9(4):046106.. View in PubMed